Doctor reacts to FDA easing restrictions on peptides

The medical community is deeply divided over the FDA advisory panel’s July 2026 decision to ease compounding restrictions on popular wellness peptides like BPC-157, TB-500, KPV, and MOTS-c. While some industry-aligned doctors praise the move for restoring autonomy to the patient-physician relationship, independent medical experts and FDA staff scientists strongly warn that the hype is severely outpacing the science, creating major risks for consumers.Become a supporter of this podcast: https://www.spreaker.com/podcast/today-explained--6659607/support.Don’t miss our latest episodes! follow us to stay updates with fresh news everyday. Let’s keep the support our podcast to serve update news entire the world!